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Abstract: Chitosan has received much attention as a functional biopolymer for diverse 
applications, especially in pharmaceutics and medicine. Our recent efforts focused on the 
chemical  and  biological  modification  of  chitosan  in  order  to  increase  its  solubility  in 
aqueous solutions and absorbability in the in vivo system, thus for a better use of chitosan. 
This  review  summarizes  chitosan  modification  and  its  pharmaceutical/biomedical 
applications based on our achievements as well as the domestic and overseas developments:   
(1) enzymatic preparation of low molecular weight chitosans/chitooligosaccharides with 
their  hypocholesterolemic  and  immuno-modulating  effects;  (2)  the  effects  of  chitin, 
chitosan and their derivatives on blood hemostasis; and (3) synthesis of a non-toxic ion 
ligand—D-Glucosaminic  acid  from  Oxidation  of  D-Glucosamine  for  cancer  and   
diabetes therapy. 
Keywords:  chitosan  derivatives;  hypocholesterolemic;  immunoenhancing;  homeostasis; 
D-Glucosaminic Acid 
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1. Introduction   
Chitosan, a natural cationic polysaccharide, has received considerable attentions as a functional, 
renewable,  nontoxic  and  biodegradable  biopolymer  for  diverse  applications,  especially  in 
pharmaceutics [1], food [2] and cosmetics [3]. In the medical field, chitosan has been developed not 
only as artificial skin, absorbable surgical suture, and a wound healing accelerator, but also as new 
physiological  materials  due  to  their  antitumor,  immunoenhancing,  antimicrobial  and 
hypocholesterolemic properties [4]. These functions have been revealed to be dependent on both their 
chemical structure and the molecular size. As a result, the application of this native polysaccharide is 
limited  by  its  high  molecular  weight  and  highly  viscous  nature  resulting  in  its  low  solubility  in 
acid-free aqueous media. In recent years, studies on the modification of chitosan have intensified since 
efficient utilization of marine biomass resources has become an environmental priority and for a better 
use of chitosan. This review focuses on the modification of chitosan by enzymatic hydrolysis and 
various  chemical  processes,  in  combination  with  pharmaceutical  and  biomedical  applications 
especially in hypocholesterolemic, immunoenhancing, homeostasic and anticancer functions, based on 
our current research as well as the recent literature. 
2. Structure and Characterization of Chitosan 
Chitosan  is  a  copolymer  consisting  of  β-(1→4)-2-acetamido-D-glucose  and 
β-(1→4)-2-amino-D-glucose units, with the latter usually exceeding 80%. The proportion of the two 
monosaccharide units in chitosan depends on the alkaline treatment Generally, the individual chains 
assume an essentially linear structure, which undergoes one full twist every 10.1–10.5 Å along the 
chain axis. Since each monosaccharide unit is chiral, the rotations of polymer chains show evident left 
or right. Accordingly, chitosan could be divided into three crystal types: α, β and γ type, which could 
be  identified  by  X-ray  model  and  NMR  spectra.  Among  these,  α-type  is  the  most  common  type 
obtained from crust of shrimp and crab [5]. 
Chitosan has three types of reactive functional groups, an amino/acetamido group as well as both 
primary and secondary hydroxyl groups at the C-2, C-3 and C-6 positions, respectively. The amino 
contents  are  the  main  factors  contributing  to  differences  in  their  structures  and  physico-chemical 
properties, and its distribution is random, which make it easy to generate intra- and inter-molecular 
hydrogen bonds.   
Many novel chitosan derivatives have been obtained by chemical modification using the reactive 
activities of hydroxy- and amino groups. In particular, the amino group has nucleophilic property, 
allowing easy formation of imine by reaction with aldehyde or corresponding amide derivatives in 
acylating reagents; in acidic solution, the amino groups showe alkaline properties and receive protons 
to generate salts, presenting cationic polymer properties. Besides, the amino functional group has also 
been correlated with chelation, flocculation and biological functions. The characterization of a chitosan 
sample requires the determination of its average Degree of acetylation (DA).The distribution of acetyl 
groups along the chain (random or blockwise) may influence the solubility of the polymer and also the 
inter-chain  interactions  due  to  H-bonds  and  the  hydrophobic  character  of  the  acetyl  group.  This 
distribution  has  been  evaluated  by  various  techniques  such  as  IR,  elemental  analysis,  enzymatic Mar. Drugs 2010, 8 
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reaction,  UV, 
1H  liquid-state  NMR  and  solid-state 
13C  NMR.  Diad  and  triad  frequencies  were 
determined for homogeneous and heterogeneous chitosan with different values of DA [6].   
Another important characteristic to consider for these polymers is the molecular weight and its 
distribution. The first difficulty encountered in this respect concerns the solubility of the samples and 
dissociation of aggregates often present in polysaccharide solutions. As to choice of a solvent for 
chitosan  characterization,  various  systems  have  been  proposed,  including  an  acid  at  a  given 
concentration for protonation together with a salt to screen the electrostatic interaction. The solvent is 
important  also  when  molecular  weight  has  to  be  calculated  from  intrinsic  viscosity  using  the 
Mark-Houwink  relation.  High  molecular  weight  chitosan  is  estimated  to  be  10
6.  High  molecular 
weight chitosans (HMWC) form solutions with higher viscosities than chitosans of lower molecular 
weight. Polymeric chitosan is soluble in acidic conditions and is insoluble at pH values above 6.3 (the 
pKa of chitosan). However, chitosan oligomer has a low viscosity, and is freely soluble at neutral pH. 
Production of low molecular weight chitosan  (LMWC) and chitooligosaccharides (COS) from the 
hydrolysis  of  chitosan  can  be  achieved  either  by  chemical  or  enzymatic  methods.  The  chemical 
method needs high energy and is hard to control; hence, the enzymatic hydrolysis of chitosan offers 
many advantages. During preparation of different molecular weight chitosans, viscosity is used as a 
parameter to determine the molecular weight. 
Unlike most polysaccharides, chitosan, LMWC and COS have positive charges, which allows them 
to bind strongly to negatively charged surfaces; this property is responsible for many of the observed 
biological activities [7]. However, it is important to mention that chitosans with different structures 
show different biological activities, and not all biological activities are found in one kind of chitosan. 
Each special type of bioactive chitosan has been developed by chemical modification and enzymatic 
hydrolysis for its potential pharmaceutical and medical application. 
3.  Enzymatic  Preparation  of  LMWC  and  COS  and  Their  Hypocholesterolemic  and 
Immunoenhancing Effects 
In  general,  for  preparation  of  COS  and  LMWC,  chitosan  can  be  hydrolyzed  enzymatically  by 
specific chitosanases and non-specific enzymes. The specific enzyme for chitosan hydrolysis has been 
found in a wide range of organisms, including bacteria [8,9], fungi [10,11] and plants [12]. Most of 
these chitosanases are characterized as endo-type and they split β-1,4 glycosidic linkages in chitosan in 
a  random  way  to  form  chitosan  oligomers.  However,  the  utility  of  these  specific  chitosanases  in 
hydrolysis is limited because of its cost and unavailability in large quantities. Nowadays, on the one 
hand, kinds of physical/chemical induction and molecular evolution of special chitosanases have been 
attempted to obtain higher activity and stability [13]. On the other hand, many researchers have been 
devoting  themselves  to  exploring  novel  sources  of  chitosanases  [14–20].  Whereby,  a  number  of 
non-specific commercial enzymes have been found for their ability to degrade chitosan with efficiency 
comparable  to  that  achieved  by  chitosanases.  Based  on  long-term  work,  we  have  made  some 
achievements  in  both  molecular  evolution  of  special  chitosanases  from  fungi  and  the 
chitosan-hydrolysis of these nonspecific enzymes as well as preparation of many kinds of LMWCs   
and COSs.   Mar. Drugs 2010, 8 
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3.1. Non-Specific Enzymatic Preparations of LMWCs and Their Hypocholesterolemic Effects 
3.1.1. Non-specific enzymatic preparations of LMWCs   
The reactions of non-specific chitosanolysis are of great interest as these commercial enzymes have 
been used in the food industry for decades [21–23] .They were found to be safe and relatively low-cost. 
Another advantage is the ease of production of LMWCs in higher yields due to their low specificity or 
nonspecificity. However, the nonspecific hydrolysis mechanisms are still disputed. Here we review the 
characterization  and  mechanism  of  chitosan  hydrolysis  based  on  the  action  of  three  typical 
non-specific enzymes: cellulase, lipase and papain.   
3.1.1.1. Cellulase-treated chitosan 
Cellulase was one of the two nonspecific enzymes firstly reported with chitosanolysis properties 
and it also exerted comparable chitosanolytic activity with the specific chitosanases. There are various 
reports  on  chitosan  hydrolysis  by  cellulases  [24–27].  We  also  studied  the  characteristics  and 
mechanism of cellulase treating chitosan. We were led to conclude that not a single chitosanolytic 
component existed in fungal commercial cellulases prepared from Trichodrma viride, exerting both 
exo-  and  endo-split  pattern.  The  commercial  cellulase  could  catalyze  the  hydrolysis  of  chitosan 
substrates with a wide range of acetyl groups and showed similar effects on chitosans with DA less 
than 30%. The optimal temperature for cellulase to function on chitosan was between 50 ºC  and 60 ºC  
and  the  optimal  pH  was  in  the  range  of  5.0  to  7.0.  The  products  of  standard  COS  and  chitosan 
digestion  were  analyzed  by  thin  layer  chromatography  (TLC),  Liquid  chromatography  mass 
spectrometry  (HPLC/MS)  and  time  course  analysis.  Results  demonstrated  that  it  could  cleave 
GlcN-GlcNAc, GlcNAc-GlcN as well as GlcN-GlcN bonds from the non-reducing end of the chitosan 
chain [28,29]. Chitosan was extensively depolymerized into a range of molecular weights (Mw) from 
286 kDa to 1588 kDa and deacetylated from 82% to 94%. Eight partial depolymerized chitosans were 
prepared [30]. About the mechanism, one bifunctional enzyme with chitosanolytic and cellulolytic 
activity  (CCBE)  from  cellulase  (T.  viride)  has  been  purified  and  further  identified  as  a 
cellobiohydrolase I with exo-β-D-glucosaminidase activity, belonging to glycosyl hydrolysase seven 
families [31,32].   
3.1.1.2. Lipase-treated chitosan   
Chitosan hydrolysis by lipase was firstly studied by Muzzarelli et al. [23]. In 2001, the degradation 
of chitosan was further studied with the aid of lipase from Rhizopus japonicus for the production of 
soluble  chitosan,  showing  that  lipase  could  degrade  chitosan  to  water-soluble  LMWC  with  Mw 
between 30–50 kDa at the optimal temperature of 40 º C [33]. In a recent study, we investigated the 
effects of a commercial lipase from A. oryzae on chitosan hydrolysis systematically with different 
parameters such as pH, temperature, DA, Mw, viscosity reduction, and qualitatively analyzed COS 
products using kinetic analysis, TLC and HPLC methods. When four chitosans with various DA were 
used as substrates, the lipase exhibited higher optimal pH toward chitosan with lower DA. The optimal 
temperature of the lipase was 55 ºC  for all chitosans. The enzyme exhibited higher activity to chitosans Mar. Drugs 2010, 8 
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deacetylated at the level of 82.8% and 73.2%. Kinetics experiments showed that these two kinds of 
chitosan also had stronger affinity for the lipase. The chitosan hydrolysis carried out at 37 ºC  produced 
larger quantity of COS than that at 55 ºC  when the reaction time exceeded 6 h, and COS yield of 24 h 
hydrolysis  at  37  ºC   was  93.8%.  Product  analysis  results  demonstrated  that  the  enzyme  produced 
glucosamine and COSs with polymerization degree (DP) of 2–6 and above, and acted on chitosan in 
both  an  exo-  and  endo-hydrolytic  manner.  Moreover,  one  main  chitosanolytic  component  with 
chitinase activity (CNBE) was purified from this commercial lipase (A. oryzae), and was identified as 
the exo-β-D-glucosaminidase with N-acetyl-chitobiosidase activity, belonging to glycosyl hydrolysase 
18 family [34,35]. 
3.1.1.3. Papain-treated chitosan 
It has been reported that papain degrades chitosan under optimal the pH condition of 3.0–4.0 and 
temperature of 40–50 ° C, although different papains were used in different researches [21,36,37]. 
Chitosan with Mw of 4–5 ×  10
5 was degraded by papain to produce the LMWC and COS in a range of 
10
3–10
5. Chitosan depolymerization was reported by papain in the form of its lactate salt at acidic pH 
values [36]. Chitosans with average molecular weights in the range of 4–7 ×  10
5 could be easily 
depolymerized to highly polydisperse chitosans. Modified chitosans were also depolymerized, though 
with lower initial velocities. The molecular parameters of chitosan depolymerized with the aid of 
papain were also studied, revealing that preference was for chitosan with highest DP. The papain 
mainly cleaved the GlcN-GlcNAc bond in chitosan [37]. However, our previous research found that 
papain could split the GlcNAc-GlcN as well as GlcN-GlcN bond and produced the mixture of LMWC 
and COS with DP of 2–6 after 24 h hydrolysis. The optimal degradation conditions were at pH 4.0 and 
40 ºC , taking 14.3% DA chitosan (0.5% concentration) as the substrate. Papain initially degraded quite 
quickly  in  the  reaction,  the  rate  of  decline  in  viscosity  was  evaluated  at  70.77%  in  30  min  then 
stabilized after 1 h. LMWCs with 4.1–56 kDa could be obtained [38]. Moreover, we discovered that 
papain has at least three hetero chitosanases responsible for its chitosanolytic activity. 
3.1.2. The hypocholesterolemic effects of different prepared LMWCs   
Growing evidence indicates that chitosan can lower plasma and liver triacylglycerol (TG) as well as 
total cholesterol (TC) levels [39–43], exhibiting hypocholesterolemic and hypolipidemic effects. It has 
been  reported  that  chitosan  can  reduce  the  risk  of  cardiovascular  diseases  [43]  and  has  potent 
fat-binding capacity in vitro [44]. In addition, chitosan was also shown to increase fecal-neutral-steroid 
and  bile-acid  excretion  in  rats  [39,41,43]  and  lower  the  postprandial  plasma  TG  level  in  broiler 
chickens [45]. Among these, the hypocholesterolemic effect of chitosan was reported in humans for the 
first time by Maezaki et al. [40], they found that chitosan effectively decreased plasma lipid levels 
without  side  effects.  However,  controversy  still  exists  surrounding  the  mechanism  of  the 
hypocholesterolemic and hypolipidemic effects of different chitosans. Taking into consideration that 
the DA and Mw of chitosan are two important characteristics  that greatly affect its chemical and 
physiological properties, in combination with the state of chitosan, our recent work studied the effects 
of  DA,  Mw  and  particle  size  of  different  solid  LMWCs  prepared  by  commercial  cellulase  on 
hypocholesterolemia in vitro and in vivo.   Mar. Drugs 2010, 8 
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The results of fat-, cholesterol- and bile-salts-binding capacities of different LMWC samples in 
vitro [30,44,46] indicated that the fat-binding capacity of LMWCs was significantly higher than that of 
cellulose, and it increased with increasing DA and Mw, while the cholesterol-binding capacity did not 
show significant variation with changes of DA and Mw, but was affected by the particle size. However, 
the bile-salt-binding capacity was greatly affected by Mw: the sample with the highest Mw showed the 
best binding capacity for bile salts, while the DA and particle size seemed to have no evident effect on 
the bile-salt-binding capacity. These results verified that the physicochemical properties of LMWCs 
affect its binding capacities and hypocholesterolemic and hypolipidemic activities in vitro. 
The hypocholesterolemic effects of LMWCs with different physiochemical properties were further 
investigated in vivo. Rats fed diets containing the lowest-DA chitosan showed significantly lowered 
plasma triglyceride, total cholesterol and low-density-lipoprotein cholesterol (LDL-C) levels as well as 
elevated  high-density-lipoprotein  cholesterol  (HDL-C)  levels,  although  not  all  differences  were 
significant. Moreover, the food-efficiency ratio also decreased with  decreasing DA  [46].This is in 
conformity with the results observed by Deuchi  et al. [47]. LMWCs with higher Mw limited the 
body-weight gain of adult rats significantly, reduced the food-efficiency ratio and lowered plasma 
lipids [46,48]. These results confirmed the effect of viscosity on hypocholesterolemic activity but also 
indicated that the viscosity was not the major factor influencing the hypocholesterolemic effects of 
chitosan  in  the  upper  gastrointestinal  tract.  Above  a  certain  viscosity,  the  effect  was  small  with 
increasing Mw. The particle size of LMWCs also evidently affected its hypocholesterolemic effect. 
LMWCs with a fine particle size effectively lowered plasma and liver lipid levels in rats [39]. In 
addition, the powdered form of LMWCs exhibited a greater rate of adsorption of oil than the flake type 
[49].  We  also  found  that  the  particle  size  of  LMWCs  was  the  main  property  affecting  its 
hypocholesterolemic effect. This is consistent with the report that powdered chitosans exhibited better 
cholesterol- binding capacity than cellulose, while chitosan in the flake form bound less cholesterol 
than cellulose [48]. 
Therefore,  we  can  conclude  that  the  physicochemical  properties  of  LMWCs  affect  their 
hypocholesterolemic  activities.  The  effects  are  more  pronounced  when  the  particles  are  finer  in 
combination with lower DA and higher Mw. 
3.1.3.  The  hypocholesterolemic  mechanism  of  LMWCs  via  adsorption,  electrostatic  force  and 
entrapment 
The hypocholesterolemic activity of LMWCs was higher when its DA was lower (90% deacetylated) 
at equal Mw and particle size; this might be due to the electrostatic attraction between LMWCs and 
anionic substances such as fatty acids and bile acids [50]. In addition, when fat and LMWCs are eaten 
together, the viscous LMWCs will entrap the fat droplets in the stomach. When the complex arrives at 
the small intestine, LMWCs precipitate together with the entrapped fat at neutral pH to prevent the 
digestion of fat; this has been proven in vitro [44]. When the DA and the particle size are comparable, 
the  fat-binding  capacity  of  LMWCs  is  enhanced  with  increasing  Mw,  suggesting  that  during  the 
fat-binding process, the fat molecules are embedded in the long chain of chitosan; hence, a larger 
molecular  weight  means  a  longer  chain  and  thus  more  fats  will  be  embedded.  Therefore,  the 
electrostatic interactions with and entrapment of fat by the viscous polysaccharide chitosan, which Mar. Drugs 2010, 8 
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would  reduce  the  absorption  of  fat  in  the  diet,  was  regarded  as  one  factor  in  the  fat-binding   
mechanism [46]. This factor also resulted in a better fat-binding capacity of chitosan than for cellulose. 
Moreover, at the same Mw, powdered chitosan has a smaller particle size, a higher total surface area 
and a more open pore structure than flake chitosan, facilitating adsorption. This suggests that the 
interaction between chitosan and bile salts as well as cholesterol is adsorption, which also contributes 
to its hypocholesterolemic effect. However, this adsorption function is likely weakened in vivo as 
chitosan can be dissolved in the acidic conditions of the stomach. 
From the above, it is a conclusion that the combined effects of electrostatic attraction, embedding, 
adsorption  and  entrapment  were  the  probable  mechanisms  of  the  hypocholesterolemic  effects  of 
LMWCs, which was further confirmed by the results of distribution and metabolism of LMWCs in rats 
through  measuring  the  content  of  fluorescein  isothiocyanate  labeled  chitosan  (FITC-CIS)  in  vivo. 
Therefore,  hypocholesterolemic  mechanisms  of  LMWCs  were  identified  as  the  combination  of 
adsorption, electrostatic force and entrapment. 
3.2. Enzymatic Preparations of COSs by Specific Chitosanases and Their Immuno-Modulating Effects 
3.2.1. Enzymatic Preparations of COSs by fungi specific chitosanases 
The higher yield and activity of special chitosanases is a long-term pursued project. Until now, the 
highest  activity  chitosanases  and  the  commercial  chitosanase  preparation  are  all  produced  from 
bacteria  such  as  Streptomycete,  most  from  which  belong  to  the  glycosyl  hydrolysase  46  family. 
However, yields were low, resulting in high costs and limitations in application. Fungi are potentially 
an excellent source of chitosanases since they secrete chitosanase extracellularly, avoiding cytotoxicity 
and product inhibition.   
Aspergillus  has  been  reported  broadly  and  is  regarded  as  a  powerful  candidate  for  special 
chitosanase  production  [11,51–54].  In  our  previous  study,  Aspergillus  CJ22-326—a  fungi  strain 
capable  of  utilizing  chitosan  as  a  carbon  source—was  isolated  from  soil  samples.  Two  types  of 
chitosanase (ChiA and ChiB) produced from the culture supernatant of Aspergillus CJ22-326 were 
purified  to  an  apparent  homogeneity,  identified  by  SDS-PAGE  through  ammonium  sulfate 
precipitation,  CM-Sepharose  FF  chromatography,  and  Sephacryl  S-200  gel  filtration.  Molecular 
weights  of  the  enzymes  were  109  kDa  (ChiA)  and  29  kDa  (ChiB).  Optimum  pH  values  and 
temperature  of  ChiA  were  4.0  and  50  ° C,  respectively,  those  of  ChiB  were  6.0  and  65  ° C. 
Viscosimetric assay and analysis of reaction products of these enzymes, using chitosan as a substrate, 
by TLC indicated endo- and exo-type cleavage of chitosan by ChiB and ChiA, respectively. ChiA 
released a single glucosamine residue from chitosan and glucosamine oligomers. ChiB catalyzed the 
hydrolysis of glucosamine (GlcN) oligomers larger than  a pentamer, and chitosan with a low DA 
(0–30%), and formed chitotriose with chitohexaose as the major products. Both of the activities of 
ChiA  and  ChiB  increased  proportionally  with  the  DA  decreasing  of  chitosan.  In  addition,  many 
chemical and physical methods have been used to improve the CHiB activity [10]. 
Furthermore, in order to improve the chitosanolytic activity, recently, both ChiA and ChiB genes 
were cloned, site-directly mutated and expressed in E. coli. The recombinant ChiB exhibited higher 
chitosanolytic activity than previously reported fungal chitosanases [55,56]. The enzyme ChiB had a Mar. Drugs 2010, 8 
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useful reactivity and a high specific activity for producing functional COS with high DP. Base on the 
amino acid similarity, ChiB exhibited high homology to other fungal chitosanases from Fusarium 
solani [57,58], which belonged to glycosyl hydrolysase 75 family.   
In addition, we also utilized the chitosanase from A. fumigatus BSF114 to produce COSs with the 
DP of 3–7. Chitosan pentamer ((GLcN)5) and chitosan hexamer ((GLcN)6) were isolated and purified 
from COS by the ultra-filtration, nano-filtration, ethanol precipitation and the CM-Sephadex C-25 
column. (GLcN)5 consisted of (GlcN)4 (59.84%) and (GLcN)5 (40.16%). (GLcN)6, however, mainly 
consisted  of  (GLcN)6 (93.11%)  and  (GLcN)5  (6.89%)  [59].  These  COSs  were  used  for  immuno- 
modulating research. 
3.2.2. The immuno-modulating effect and mechanism of COSs   
Previous  studies  showed  that  COS  possesses  not  only  some  similar  properties  with  chitin  and 
chitosan, but also special physiological or functional properties that differ from chitin and chitosan 
[60]. Immune activities of COS have attracted interest among researchers [61]. A LMWC and a COS 
mixture  isolated  from  this  chitosan  hydrolysate  have  different  stimulatory  effects  on  the  cell 
proliferation and IgM secretion of the human hybridoma HB4C5 cells [62]. Oligochitosan consisting 
of chitohexaose has been reported to have a stimulatory effect on the release of interleukin 1β (IL-1β) 
and necrosis factor-alpha (TNF-α) in macrophages in vitro [63]. A quantity of investigations indicated 
that the immunoregulatory function of polysaccharide is due to the combination of polysaccharide and 
the lymphocyte surface receptor, namely complement III receptor (CR3). However, effect of the DP of 
COS  on  gene  expression  and  secretion  of  cytokines  was  not  understood.  Herein,  the  immune 
mechanism of higher DP chitooligomers ((GLcN)5 and (GLcN)6) obtained by enzymatic hydrolysis of 
chitosan on gene expression was studied. 
CR3  was  initially  described  as  an  opsonic  receptor.  Subsequently,  CR3-mediated  lectin-sugar 
recognition  mechanisms  have  been  shown  to  play  a  major  role  in  the  phagocytosis  of  several 
pathogens [64]. Effects of (GLcN)5 and (GLcN)6 in vivo and in vitro on gene expression of cell surface 
CR3  receptor  were  investigated  by  relatively  quantitative  reverse  transcription-polymerase  chain 
reaction (RT-PCR) and Enzyme-linked immunosorbent assay (ELISA). The results showed that the 
expression of CR3 mRNA could be promoted by both (GLcN)5 and (GLcN)6. The promotion effect 
caused  by  (GLcN)6  was  greater  than  that  of  (GLcN)5.  The  possible  mechanism  was  that  the 
polysaccharide bound the binding site of CR3 and changed the configuration of the receptor. The 
change of configuration can adjust the toxicity of target cells conditioned by iC3b. After binding to the 
CR3 receptor, (GLcN)5 and (GLcN)6 can activate phagocytes to improve the phagocytic ability and 
enhance the antibody transmission ability. Moreover, it can activate T cells and B cells and enhance 
their conjugated effect in the immune response. The molecular weight of (GLcN)6 is higher than that 
of (GLcN)5, and relatively, the amount of amino groups exposed of (GLcN)6 is also larger than that of 
(GLcN)5. Therefore, (GLcN)6 has more active binding sites to combine with the CR3 receptor surface 
of macrophage and lymphocyte. And also (GLcN)6 can change the configuration of CR3 receptor to 
show higher affinity for CR3 receptor [59]. 
Moreover, the effect of COSs on gene expression of important cytokines such as IL-1 and TNF-α in 
Mf as well as IL-2 and interferon-γ (IFN-γ) in lymphocytes were also studied using cell proliferation Mar. Drugs 2010, 8 
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assay  in  our  team.  Our  results  indicated  that  (GLcN)6  and  (GLcN)5  could  promote  the  immune 
mediation of mice in relation with the gene transcription level of IL-1,TNF-α and IFN-γ as well as the 
protein translation level of these cytokines. The promotion effects caused by (GLcN)6 were greater 
than that of (GLcN)5 [65]. This result was in accordance with previous reports [66–68]. After mice 
were treated with chitin oligosaccharides or chitosan oligosaccharides, Mf were activated and adjusted 
mutually with other components of the immune system which hastened the production of reactive 
medium  such  as  reactive  oxygen  and  NO  [67].  COSs  could  either  directly  kill  pathogen 
micro-organisms or tumor cells by exerting an immune response, or enhance cytotoxic activity and 
then inhibit tumor cell production by activating T-cells, NK-cells and some other immune cells through 
some cytokines such as IL-1 and TNF-α [67,69]. TNF-α could exert synergetic effects and adjust the 
proliferation of Th1 cell systems together with IL-1 and IL-2 in vitro [69]. These results indicate that 
COS induced innate immune responses by up-regulating IL-1, TNF-α and IFN-γ and then played a role 
in immune functions of lymphocytes. This may be one of the molecular mechanisms for elucidating 
the immunity of COS. 
4. Hemostasis Effects of Chitosan and Its Derivatives   
4.1. Quality Requirements for Chitosan as a Hemostasis Material 
Research showed that whole blood formed a coagulum rapidly upon exposure to chitosan [70]. The 
following studies have shown that chitosan acts as a hemostatic agent and may be used in various 
wound healing applications such as hemostatic bandages [71–73]. However, chitosan, only in its purest 
form, has an internal hemostatic dressing potentiality, as a drug delivery agent, tissue scaffolding and 
numerous  other  health related  products  [74,75]. As a  natural  product derived from the shells and 
components of organisms found in natural environments, chitosan carries a variety of contaminants, 
common to biologically derived materials such as protein and endotoxin, which varies from batch to 
batch, and thus must be carefully purified; subsequently, the resultant stimulatory immune responses in 
humans and animals is to be understood prior to medically related applications [76,77].  Recently, 
various chitosan-containing medical devices such as the hemostatic Celox for the treatment of bleeding, 
and bandages such as HemCon or QuikClot for the control of bleeding, are marketed in Europe and US 
[74].  These  companies  utilize  processes  that  eliminate  contaminants  such  as  proteins,  bacterial 
endotoxins  and  toxic  metals,  practicing  Good  Manufacturing  Practice  (GMP)  guidelines.  Besides, 
there are many reports on the preparation of high purity chitosan for medical grade through getting rid 
of the protein, lipid, metals and endotoxin [78–88] and chitins contaminated by metals are unsuitable 
for the preparation of medical grade chitosan. 
4.2. The Hemostatic Effect of Chitosan and Its Derivatives   
4.2.1. The hemostatic effect of chitin and chitosan 
Since Muzzarelli described the properties of chitin in human wounds in 1977 [89], a lot of research 
has been initiated all over the world into the hemostatic activities of chitin and chitosan [90–94]. The 
effects of chitin and chitosan suspensions (0.0001–1.0 mg/mL) on blood coagulation were evaluated Mar. Drugs 2010, 8 
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by Okamoto et al., the results of the blood coagulation time (BCT) showed that chitin and chitosan 
reduced BCT significantly in a dose-dependent manner, and they enhanced the release of the platelet 
derived  growth  factor-AB  (PDGF-AB)  and  the  transforming  growth  factor-β1  (TGF-β1)  from  the 
platelets, particularly with chitosan [90]. Even in a therapeutically anticoagulated (heparinized) rabbit 
model, chitosan treatment could effectively bring bleeding time within the normal range [91]. The 
same  conclusion  was  reached  when  Wang  et  al.  compared  the  hemostatic  ability  of  chitosan  and 
collagen sponge. For both chitosan and collagen sponges, the total amount of bleeding from the injured 
veins  until  hemostasis  and  the  complete  hemostasis  success  rates  were  similar.  But  the  chitosan 
sponges strongly adhered to the surface of the rabbit muscles, whereas the collagen sponges were 
easily detached from the muscles [92]. A fly-larva shell-derived chitosan sponge (CS) was evaluated as 
an absorbable surgical hemostatic agent in a rat hepatic hemorrhage model [93], indicating that CS was 
a suitable implantable hemostatic material when compared to gelatin sponge or oxidized cellulose in 
both acute and chronic bleeding models. Recently developed internal chitosan bandages have been 
effective in achieving rapid hemostasis in large surgical and traumatic lacerations of the aorta, liver, 
lung, kidney and cardiac ventricles [94]. However, there is little research on the blood coagulation of 
chitosans  with  different  physicochemical  properties.  Our  recent  study  measured  the  in  vitro 
coagulative activity of chitosan hydrochloride solution with different DA and Mw using tube and 
capillary tube methods. The results indicated that the DA and Mw of chitosan had great influence on 
the hemostasis of chitosan hydrochloride solution: this chitosan with higher DA and Mw exhibited 
better hemostatic activity, while the effect of DA and Mw was slight on the powder chitosan. From this, 
it can be deduced that the hemostatic mechanisms of chitosan in powder and hydrochloride solution 
were different. Meanwhile, organ damage in vivo experiments in rabbits showed that chitosan could 
promote rapid blood clotting at a wound injury in lung, spleen and kidney, and also reduce the amount 
of bleeding, exerting a good in vivo hemostatic effect. 
4.2.2. The hemostatic effect of chitosan derivatives 
Based on the excellent hemostatic activity, lots of chitin and chitosan derivatives with different 
chemical  or  spatial  structures  have  been  explored.  N,O-carboxymethylchitosan  (NOCC)  could 
decrease the whole blood clotting time (WHBCT) and lower the plasma recalcification time (PRT) 
value, similar to that of chitosan and chitin [95]. When used in a hypothermic coagulopathic grade V 
liver injury, Bochicchio et al found that a modified chitosan patch (MCP) could significantly reduce 
the  post  treatment  blood  loss  and  increase  resuscitation  mean  arterial  pressure  (P  <  0.0001  and   
P < 0.018, respectively) [96]. The photocrosslinkable chitosan (Az-CH-LA) is a chitosan hydrogel 
containing both lactose moieties and photoreactive azide groups. The sealing ability of this chitosan 
hydrogel expressed stronger similarity to that of fibrin [97]. The photocrosslinkable chitosan has been 
used for endoscopic cancer treatment in the alimentary tract [98]. It could completely stop the bleeding 
from a cut mouse tail within 30 s of UV-irradiation and could firmly adhere two pieces of sliced mouse 
skin to each other. Its hemostatic effect is independent of the blood coagulation [99]. Moreover, a 
series of new in situ-forming hydrogels, composed of oxidized dextran (Odex) and amine-containing 
polymers including polyallylamine (PAA), oligochitosan and glycol chitosan, have been developed 
[100]. Some scholars also explored chitosan derivatives with the amino group introduction by using Ar, Mar. Drugs 2010, 8 
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O2, NH3 and NH3-He mixed gas plasmas [101].These samples all showed shorter blood clotting time, 
while the best was with treatment by NH3 and He plasma with O2 pretreatment. 
Among  these,  chitosan-Glycerol  Phosphate  hydrogels  were  the  most  attractive,  and  have  been 
deeply developed [102,103]. Chitosan-glycerol phosphate (chitosan-GP) is a unique polymer solution 
that is mixed with whole blood and solidified over microfractured or drilled articular cartilage defects 
in  order  to  elicit  a  more  hyaline  repair  cartilage  [104].  It  was  found  by  Buschmann  [102]  that 
chitosan-GP/blood clots showed increased adhesion to the walls of the defects as compared with the 
blood clots in the untreated microfracture defects. After histological processing, all blood clots in the 
control microfracture defects had been lost, whereas chitosan-GP/blood clots adhered to and were 
partly  retained  on  the  surfaces  of  the  defect.  At  six  months,  defects  that  had  been  treated  with 
chitosan-GP/blood were filled with significantly more hyaline repair tissue (p < 0.05) compared with 
control  defects.  Repair  tissue  from  medial  femoral  condyle  defects  that  had  been  treated  with 
chitosan-GP/blood contained more cells and more collagen compared with control defects and showed 
complete  restoration  of  glycosaminoglycan  levels.  These  results  indicated  that  solidification  of  a 
chitosan-GP/blood  implant  in  microfracture  defects  improved  cartilage  repair  compared  with 
microfracture alone by increasing the amount of tissue and improving its biochemical composition and 
cellular organization. Later, they further studied the effects of the chitosan-GP/blood implant and of 
debridement  on  the  formation  of  incipient  cartilage  repair  tissue  by  histology  and  in  vitro  clot 
retraction tests [103]. They found that chitosan-GP solutions structurally stabilized the blood clots by 
inhibiting clot retraction. Chitosan-GP/blood implants applied in conjunction with drilling, compared 
to  drilling  alone,  elicited  a  more  hyaline  and  integrated  repair  tissue  associated  with  a  porous 
subchondral bone replete with blood vessels. Concomitant regeneration of a vascularized bone plate 
during  cartilage  repair  could  provide  progenitors,  anabolic  factors  and  nutrients  that  aid  in  the 
formation  of  hyaline  cartilage.  In  addition,  a  series  of  chitosan-polyphosphate  dressings  were 
fabricated and the optimal chitosan-polyphosphate formulation (coded as ChiPP) accelerated blood 
clotting (p = 0.011), increased platelet adhesion (p = 0.002), generated thrombin faster (p = 0.002), and 
absorbed more blood than chitosan (p < 0.001) [106]. 
Table 1. Some commercial hemostatic dressings based on chitosan [104,105,107–109]. 
Commercial name  Company  Material and function 
HemCon®  HemCon  Freeze-dried chitosan acetate salt, for emergency use to stop bleeding 
Chitoflex®  HemCon 
Based on chitosan, antibacterial, biocompatible wound dressing designed to be stuffed 
into a wound track to control moderate to severe bleeding 
Chitoseal®  Abbott  Based on chitosan, backed with cellulose coating, for bleeding wounds 
Clo-Sur®  Scion  Based on chitosan, a pressure pad applied topically to accelerate wound healing 
TraumaStat®  Ore-Medix  Freeze-dried chitosan containing highly porous silica 
Syvek-Patch® 
Marine Polymer 
Technologies 
Made of fully acetylated, high molecular-weight chitin in a crystalline, three-dimensional 
beta structure array, and isolated from the centric diatom Thalassiosira fluviatilis . It is 
claimed to be 7 times faster in achieving hemostasis than fibrin glue, because it 
agglutinates red blood cells, activates platelets whose pseudopodia make robust contact 
with chitin and promotes fibrin gel formation within the patch, thus acting in a redundant 
way even on heparinized patients 
BST-CarGel®  Biosyntech company  chitosan-glycerophosphate hydrogels, a biodegradable gel for cartilage repair Mar. Drugs 2010, 8 
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Based on the hemostatic properties reported from studies of chitin, chitosan and their derivatives, 
commercial chitin- and chitosan-based hemostatic dressings have flooded the market (see Table 1) and 
are used in medicine.   
4.3. The Hemostatic Mechanism of Chitosan and Its Derivatives 
Due to the effects of chitosan and its derivatives on hemostasis, there are lots of reports on studies 
of the mechanism in vitro and in vivo. Although there is still no assured verdict of the mechanism by 
which  they  function  to  stop  bleeding,  several  factors  are  thought  to  contribute  to  the  hemostatic 
function. 
4.3.1. The hemostatic mechanism of chitosan 
Studies indicate that chitosan’s hemostatic mechanism seems to be independent of the classical 
coagulation  cascade  [110].  It  has  been  found  that  coagulation  factors  could  not  be  activated  by 
chitosan and its derivatives [111], and no activation of the intrinsic pathway was observed by Benesch 
et al. [112]. Chitosan’s putative capacity to induce clot formation in the absence of coagulation factors 
could  prove  to  be  useful  for  patients  with  coagulopathies  or  those  who  are  therapeutically 
anticoagulated, since chitosan keeps ability to maintain hemostasis in the presence of heparinized 
blood. Most of all, numerous articles reported the interactions between chitin/chitosan and platelets 
[113–115]. These studies suggested that chitin and chitosan directly influenced platelets by themselves 
and this effect was enhanced in the presence of plasma. Some researchers regarded that chitosan likely 
function independently of platelets because it could induce clot formation in the absence of platelets 
[111,116], however, over time, more and more researchers admit that the hemostatic effects of chitosan 
are related to both platelets and erythrocyte aggregations. The blood clot formed in the chitosan-treated 
lingual  incisions  was  evaluated  by  scanning  electron  microscopy,  and  it  showed  an  interesting 
phenomenon:  when  the  blood  mixed  with  chitosan  acetic-acid  physiological  saline  solution,  the 
erythrocytes  aggregated  and  were  deformed.  The  deactylation  degree  in  the  chitosan  acetic  acid 
physiological saline solution - especially a low deactylation degree - had a significant effect on the 
unusual aggregation and deformation of erythrocytes, compared with the effect of Mw within a range 
between  10
5  and  10
6.  However,  this  phenomenon  could  not  be  observed  in  solid-state  chitosan 
soliquoid [116]. Our recent research also demonstrated that the hemostasis of chitosan has no direct 
relation  to  the  traditional  intrinsic  or  extrinsic  pathways,  but  it  could  promote  the  adhesion  and 
aggregation  of  platelets.  Platelets  play  a  very  important  role  in  coagulation  and  could  promote 
hemostasis  and  thrombosis.  The  membrane  space  configuration  changes  and  the  platelet-derived 
microparticles (PMPs) are released in the activated platelets, then the exposed platelet glycoprotein 
IIb-IIIa receptor complex interacts with fibrinogen, resulting in platelet accumulation, and ultimately 
initiating the chain reaction of coagulation. Binding or agglutination of red blood cells in the presence 
of chitosan is dependent on its physical characters, particularly on molecular size. The ionic attraction 
between negatively charged red blood cell membranes and positively charged groups in chitosan is a 
possible explanation for the anticoagulant activity of chitosan. Therefore, positively charged chitosan 
is more effective than chitin as a blood coagulant [113]. Mar. Drugs 2010, 8 
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Except for platelets and erythrocytes, chitosan also accelerated thrombin generation in a statistically 
significant  manner  compared  to  the  saline  control,  with  a  trend  towards  chitin  being  more 
thrombogenic [117]. Upon acetylation, the chitosan layer became a strong activator of the alternative 
pathway of the complement system [115]. 
4.3.2. The hemostatic mechanism of chitosan derivatives 
Except for the hemostatic mechanism of chitosan itself, the hemostatic responses to its derivatives 
highly depend on their chemical nature such as the added functional groups. Hence, different chitosan 
derivatives are involved in different hemostatic mechanisms. For example, carboxymethyl chitosan 
physiological saline solution had nothing to do with the aggregation and deformation of erythrocytes 
but  caused  local  rouleau  [115].The  morphology  of  red  blood  cells  binding  surface  on  chitin  and 
chitosan  was  examined,  with  approximately  10-fold  lower  levels  and  with  less  distinct  general 
morphologies than the highly structured β-pGlcNAc [118].   
Chitosan-glycerol  phosphate  (chitosan-GP) is one  of the  most popular  chitosan derivatives and 
underwent detailed research by the company Buschmann and Biosyntech through investigating the 
hemostatic  mechanisms  underlying  chitosan-GP/blood  implant  solidification  in  vitro  and  in  vivo 
[103–105,119]. They found that chitosan-GP/blood clots solidified in an atypical biphasic manner, 
with higher initial viscosity and minor platelet activation followed by the development of clot tensile 
strength concomitant with thrombin generation, burst platelet and FXIII activation. Whole blood and 
chitosan-GP/blood  clots  developed  a  similar  final  clot  tensile  strength,  while  polymer-blood  clots 
showed a unique, sustained platelet factor release and greater resistance to lysis by tissue plasminogen 
activator.  Thrombin,  tissue  factor  (TF),  and  recombinant  human  activated  factor  VII  (rhFVIIa) 
accelerated  chitosan-GP/blood  solidification  in  vitro  (P  <  0.05).  Pre-application  of  thrombin  or 
rhFVIIa+TF  to  the  surface  of  drilled  cartilage  defects  accelerated  implant  solidification  in  vivo   
(P  <  0.05).  In  conclusion,  chitosan-GP/blood  implants  solidify  through  coagulation  mechanisms 
involving  thrombin  generation,  platelet  activation  and  fibrin  polymerization,  leading  to  a  dual 
fibrin-polysaccharide clot scaffold that resists lysis and is physically more stable than normal blood 
clots. Clotting factors have the potential to enhance the practical use, the residency, and therapeutic 
activity of polymer-blood implants [119]. 
5. Synthesis of D-Glucosaminic Acid by Oxidation from D-Glucosamine: A Useful Metal Chelate 
for Anticancer and Anti-Diabetic Purposes 
D-glucosamine is a structural unit of chitosan, and is produced commercially by the hydrolysis of 
chitosan  in  hydrochloric  acid.  D-glucosamine  could  be  oxidized  to  D-glucosaminic  acid. 
D-glucosaminic acid is one of the carbohydrate units used to manufacture various biotic substances. It 
has various physiological functions. 
5.1. Biological Activities of D-Glusosaminic Acid 
In recent years, research on D-glucosaminic acid has increased because of its industrial, agricultural, 
food  and  medical  applications.  D-glucosaminic  acid  has  recently  been  identified  as  a  promising Mar. Drugs 2010, 8 
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sweetener and condiment [120]. It is also a member of the ―chiral pool‖ and has been used as a starting 
material  for  the  asymmetric  synthesis  of  various  amino  acids  and  several  glycosidase  inhibitors 
[121,122]. In addition, D-glucosaminic acid has recently been investigated as an unusual component of 
Rhizobium leguminosarum lipopolysaccharide [123], and its use as a cation coordinating agent has 
been widely studied [124]. Among these, the most remarkable was investigation of D-glucosaminic 
acid  as  a  biocompatible,  non-toxic  ligand  chelated  with  many  metals  for  potential  medical 
applications.   
D-glucosaminic acid iron (III) complexes are potential pharmaceuticals in human and veterinary 
iron  therapy  since  their  stabilities  are  high  enough  to  prevent  metal  ion  hydrolysis  in  biological 
systems. Water-dispersed magnetic nanoparticles were successfully developed through glucosaminic 
acid-surface modification of iron oxide nanoparticles and its anticancer effect was then studied by Yu 
et al. [125]. The resultant glucosaminic acid-modified magnetic nanoparticles (GA-MNPs) had not 
only good uniformity in spherical shape with diameter of about 10–13 nm, but also possessed excellent 
water-dispersal and stability. In cell culture experiments, the internalization of GA-MNPs into different 
kinds of cells was observed over a five-day period. The results indicated that the internalization of 
GA-MNPs into mouse macrophage cells and mouse embryonic fibroblast cells was not observed after 
40 h of culturing. However, the GA-MNPs were internalized quickly into cancer cells after just 24 h of 
culturing.  TEM  images  of  the  GA-MNPs  uptake  in  ECA-109  cells  were  used  to  study  the 
internalization mechanisms of GA-MNPs and their distribution in ECA-109 cells. Besides this, the 
platinum(IV)/D-glucosaminic  acid  complex  has  received  considerable  attention  for  cancer  therapy 
because of lower toxicity and the possibility of oral administration [126].   
Moreover,  D-glucosaminic acid has also been selected to design a new kind of chromium drug 
candidate  for  anti-diabetic  purposes  [127].  Two  chromium  (III)  1:1  and  2:3  (Cr:  glucosaminate) 
complexes of glucosaminic acid were synthesized by neutralization and exchange reaction. The effect 
of the complexes on decreasing blood sugar was investigated on type-2 diabetes model rats induced by 
tetraoxypyrimidine. The results indicated that the effect on decreasing blood sugar was comparable to 
that of picolinate chromium complex (Cr (pic)3) currently used worldwide. 
5.2. Synthesis of D-Glucosaminic Acid by Oxidation from D-Glucosamine 
The  molecular  structure  of  D-glucosaminic  acid  [128]  is  shown  in  Figure  1.  Three  synthesis 
strategies  have  been  reported  for  D-glucosaminic  acid  from  D-glucosamine:  metallic  catalytical 
oxidation, electrocatalytical oxidation and biosynthesis methods. A summary of the methods is given 
in the following context. 
Figure 1. The molecular structure of D-glucosaminic acid. 
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Figure 1 The molecular structure of
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5.2.1. Metallic catalytic oxidation method 
5.2.1.1. Oxidations with HgO and Hg(Ac)2 
The classical synthesis of  D-glucosaminic acid from  D-glucosamine involves the use of yellow 
mercuric oxide as an oxidant [129], or mercuric acetate [130], followed by treatment with hydrogen 
sulfide, in a totally non-ecological process. One century ago, the yields of these procedures were not 
consistent (about 54%) and the resulting mercuric sulfide was difficult to separate from the products, 
which limited applications of D-glucosaminic acid in the food and pharmaceutical industries. However, 
recently we chose one novel separation method, the process was effective in a short time and the purity 
was higher than 95%. The yield of production through this process was estimated at a minimum of 
50% of the amount of D-glucosamine chloride in use. 
5.2.1.2. Platinum and Palladium Catalyzed Oxidations 
The oxidation of mannose over a platinum black catalyst was the first application in the field of 
carbohydrates [131]. Subsequently, the catalytic oxidation of carbohydrates over platinum on carbon 
was extensively studied [132–134]. Like platinum, the related noble metals palladium and rhodium are 
known to catalyze alcohol oxidations with O2. The oxidation of carbohydrates catalyzed by platinum 
and palladium has been reviewed a number of times [133]. D-glucosamine can also be oxidized by O2 
with platinum and palladium catalysts, as can be seen in Table 2.   
Table  2. The  oxidation  of  D-glucosamine to  D-glucosaminic  acid by (promoted)  noble 
metal catalysts [128]. 
Catalyst  Yield 
PtO2  37% 
Pd  54–60% 
Pd-Bi (yield: 70%)  70% 
Based  on  our  recent  research  and  the  literature,  we  concluded  that  the  noble  metal  catalyzed 
oxidation  of  D-glucosamine  to  D-glucosaminic  acid  is  essentially  an  oxidative  dehydrogenation 
reaction, like alcohols and aldehydes (see Figure 2). The substrate is dehydrogenated by the noble 
metal, followed by oxidation of the adsorbed hydrogen atoms. Poisoning of the catalyst by molecular 
oxygen  occurs  by  formation  of  sub-surface  platinum  or  palladium  oxide  resulting  from  oxygen 
adsorption of the surface in the absence of a reducing agent. This poisoning can be limited using a low 
oxygen pressure but cannot be precluded entirely. However, the catalyst can be regenerated using 
hydrogen  as  the  reducing  agent  to  regain  the  original  activity.  Otherwise,  this  poisoning  can  be 
precluded entirely by using both Pd and Pt catalysts doped with bismuth, where bismuth acts as an 
assistant catalyst, avoiding the overoxidation of the palladium and platinum surface. For this reason, 
the yield of D-glucosaminic acid with active charcoal supported Pd-Bi catalyst is much higher than 
with the other catalysts. Moreover, the preparation of D-glucosaminic acid by use of molecular oxygen 
as  an  oxidant  and  Pd-Bi/C  as  a  catalyst  presents  some  additional  advantages,  namely,  (i)  high 
selectivity and mild reaction conditions (oxidation with molecular oxygen at atmospheric pressure near Mar. Drugs 2010, 8 
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room temperature); (ii) the possibility of conducting the oxidation in one step in a single reaction 
vessel; (iii) a higher site-time yield per catalyst mass; (iv) a much shorter reaction time (3 h). Moreover, 
the catalytic process is environmentally clean since it is conducted on recyclable catalysts and gives no 
noxious  effluents  or  side  products.  Therefore,  this  method  is  more  attractive  for  the  oxidation  of 
D-glucosamine [128]. The method further aims to ensure easy removal of the catalyst from the reaction 
mixture  and  to  enhance  its  mechanical  stability,  as  well  as  to  enable  operation  in  a  fixed  or   
suspended bed. 
Figure 2. Tentative scheme for the mechanism of D-glucosamine hydrocloride oxidation 
on Pd-Bi/C catalyst [128]. 
5.2.2. Biosynthesis methods 
Two  main  strategies  including  enzymatic  and  microbiological  methods  are  used  to  synthesize 
D-glucosaminic acid from D-glucosamine. A combination system of glucose oxidase (EC 1.1.3.4) and 
Catalase (EC 1.11.1.6) has high catalytic activity (yield: 76%) in an aqueous solution of pH 7 [135]. It 
has been reported that some microbes, such as Acinetobacter sp., Aerobacter sp., Acetobacter sp. and 
Escherichia  sp.,  produce  D-glucosaminic  acid  from  D-glucosamine  [136–141].  As  to  enzymatic 
oxidation, D-glucosaminic acid was prepared by air oxidation of D-glucosamine catalyzed by glucose 
oxidase.  However,  glucose  oxidase  accepts  D-glucosamine  only  as  a  poor  substrate;  the  maximal 
catalytic efficiency was 2%. Thus, a better yield of  D-glucosaminic acid was dependent on larger 
amounts of enzyme conjugated to longer reaction times (72 h).   
Biosynthesis methods include many more procedures, such as culturing of strains, screening of 
strains, sterilization, etc. Currently, strict temperature controls, more by-products, longer reaction times, 
and lower purity of products limit the development of these methods. Therefore, the development of 
these methods requires many technological problems to be solved. 
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5.2.3. Electrocatalytical oxidation   
Electrocatalytical oxidation of D-glucosamine was first reported by Yao et al. [142]. The authors 
discussed  the  oxidation  of  glucose  and  derivatives  at  platinum  black  electrodes  in  pH  7.4  saline 
solution (isotonic with human plasma) with the objective of determining the feasibility of consuming 
such materials in an implantable energy conversion device. The anodic process would be oxidation of 
carbohydrates at an electrode with an associated diffusion membrane to prevent contact with blood or 
intercellular fluid, and the cathodic process would be reduction of oxygen. The catalytical effects of 
different electrode materials on the anodic oxidation process were further researched by Appleby and 
Drunen [143]. The results obtained indicate that platinum, rhodium and Pt-Ru alloy electrodes are 
effective  for  glucose  and  D-glucosamine  oxidations.  In  2007,  Tominaga  et  al.  [144]  fulfilled  the 
synthesis  of  D-glucosaminic  acid  using  the  novel  approach  of  the  electrocatalytic  oxidation  of 
D-glucosamine using gold electrodes and gold nanoparticle-modified carbon electrodes. The cyclic 
voltammetric results obtained indicated that D-glucosamine was catalytically oxidized in alkaline and 
neutral solutions. The controlled-potential electrolysis of D-glucosamine was possible in both alkaline 
and neutral solutions, and D-glucosaminic acid was identified as the 2-electron oxidation product. In 
particular,  in  an  alkaline  solution  at  a  potential  of-0.2  V,  D-glucosaminic  acid  was  formed  as  the 
2-oxidation products with a current efficiency of 100%. When compared to the conventional synthesis 
method of D-glucosaminic acid, this synthesis approach is a useful alternative. 
Although  the  electrocatalytical  oxidation  method  overcomes  the  disadvantages  of  biosynthesis 
methods,  such  as  more  by-products  and  complicated  processes,  it  is  seldom  adopted  in  industrial 
produce due to the higher energy consumption and the difficulty to control conditions. 
In a word, although much research has been done on the synthesis of  D-glucosaminic acid by 
metallic  catalytical  oxidation,  electrocatalytical  oxidation  and  biosynthesis  methods,  industrialized 
synthesis of D-glucosaminic acid has not yet been realized. The biosynthesis method produces higher 
yields, but some technological problems must be solved regarding the complicated procedures, such as 
separation of products, culture and screening of strains, etc. The noble-metal catalyzed oxidations with 
carbohydrates and derivatives have received increasing attention in recent years. In a number of cases, 
the selectivity of these catalytic processes can match those of enzymatic processes with the additional 
advantages of higher site-time yields and cleaner technologies. Thus, this method has received more 
and more attention. It is a promising synthesis method for D-glucosaminic acid in industry. However, 
there  are  still  some  parameters  to  be  clarified  in  order  to  fulfill  the  necessary  requirements  for 
industrial development, such as an appropriate preparation system for catalysts and improvement of 
activity, stability and selectivity of catalysts. 
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